Authors
Latest:
ACHIEVING IMPROVED OUTCOMES THROUGH PARTNERSHIPS BETWEEN OPTOMETRISTS AND RETINA SPECIALISTSConsiderations in the treatment of diabetic retinopathy and diabetic macular edema.
Latest:
Managing neovascular retinal disease in COVID-19 era requires careful approachMinimizing clinic visits, maximizing use of imaging modalities are key.
Latest:
Final Pearls on Managing Dry Eye Patients With ComorbiditiesOphthalmologists end their discussion on the management of dry eye disease with other ocular comorbidities highlighting key takeaways and prospective advances in care and outcomes.
Latest:
ACHIEVING IMPROVED OUTCOMES THROUGH PARTNERSHIPS BETWEEN OPTOMETRISTS AND RETINA SPECIALISTSConsiderations in the treatment of diabetic retinopathy and diabetic macular edema.
Latest:
Focusing on postinjection endophthalmitisSystemic immunosuppression may prevent devastating complication in patients.
Latest:
Seize underutilized opportunity to treat glaucoma during vitrectomyOphthalmologists can reduce IOP and medications with endocyclophotocoagulation while in the eye.
Latest:
Benefits of topography-guided treatments for irregular corneasProcedure can improve best-corrected visual acuity, enhancing quality of life for patients.
Latest:
The evolving role of vitreosurgical simulators in surgical trainingNeed to eliminate errors results in optimization of training of novice surgeons.
Latest:
Considerations for the Future of Biosimilars in the Treatment of Retinal DisordersCarl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.
Latest:
Weighing treatments for chronic postop cystoid macular edemaPrompt and adequate action is a key to facilitating the best recovery in patients.
Latest:
FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasisOcuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
Latest:
Increasing your practice’s reach, relevance, and revenue with clinical trialsWorking as an investigator can prove to be a positive experience for physicians
Latest:
The eyes offer conjunctival clue to COVID-19A patient's vision loss leads to another diagnosis
Latest:
What’s Your WhEYE? A conversation with Paul Badawi, CEO of Sight SciencesPaul Badawi, co-founder and CEO of Sight Sciences, sits down with host Neda Shamie, MD, to discuss his journey into the field of eye care, what motivates him, the transformative approach to glaucoma patient care, and the spark that led him and his ophthalmologist brother, David Badawi, MD, to start the company together.
Latest:
Patient case 2: DME Patient Treated with Ranibizumab BiosimilarDilsher S. Dhoot, MD discusses a recent case-based roundtable meeting on anti-VEGF biosimilars, highlighting the first of two case discussions.
Latest:
Future Directions of Retinal Eye DisordersDilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss future directions and unmet needs in the field of retinal eye disease.
Latest:
Driving practice growth: Expand on link between dry eye, aestheticsOne obvious trend has been that dry eye disease is a concurrent problem for virtually all my patients, and we need to address it for optimum comfort and surgical results.
Latest:
Ophthalmologists embrace potential of clinically tested nutraceuticals for dry eye diseaseLook beyond isolated treatment of the eye to address systemic factors.
Latest:
Protection of eyes during prone positioning must be routinely monitored in ICUTreatment of patients with COVID-19 should include ophthalmic considerations.
Latest:
VLOG: Neuro-Ophthalmology interprofessional eConsultsAndrew Lee, MD, Andrew Carey, MD, and Elizabeth Fortin, MD, sit down on this episode of the NeuroOp Guru to discuss neuro-ophthalmology, interprofessional eConsults, and whether they provide timely and valuable guidance
Latest:
Patient outcomes and intraoperative use of phenylephrine/ketorolac 1%/0.3%ICYMI: Denise Visco, MD, shares the take-home message from her 2019 ASCRS presentation.
Latest:
Neuropathic dry eye: When serum defeats tearsOphthalmology Times is pleased to announce Melina I. Morkin, MD, and Pedram Hamrah, MD, FACS, of New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, as the third-place winner of the 2017 Resident Writer’s Award Program, sponsored by Allergan. Their entry is featured here.
